QuickView for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=84A7B1B8F90E10C4BB8EF198E8862C87;jsessionid=086624F9ED561E2247AC960DF604F403;jsessionid=47BD8608FF341F1D3328BD9EEC561979;jsessionid=A043B438A3B5591667B8740B38982408;jsessionid=9027B536D2550EDF7D878A47D533B0C4;jsessionid=443788A5644E2BC100B4B2DB7758A0F8;jsessionid=D5910CF695459A7E16D5E2ED4D57B26D;jsessionid=ADB88245153F47A8DB7FFAB918534039;jsessionid=419D678EC78D9600BBD4A29EF0D1DC70 (gene)

1. Ataxin-2 sequesters Raptor into aggregates and impairs cellular mTORC1 signaling.
2. ATXN2 is a target of N-terminal proteolysis.
3. A Case of Coexistent Spinocerebellar Ataxia Type 2 and Primary Progressive Multiple Sclerosis-Coinci…
4. ATXN2 intermediate expansions in amyotrophic lateral sclerosis.
5. TDP-43 impairs sleep in Drosophila through Ataxin-2-dependent metabolic disturbance.

There were no clinical trials for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=84A7B1B8F90E10C4BB8EF198E8862C87;jsessionid=086624F9ED561E2247AC960DF604F403;jsessionid=47BD8608FF341F1D3328BD9EEC561979;jsessionid=A043B438A3B5591667B8740B38982408;jsessionid=9027B536D2550EDF7D878A47D533B0C4;jsessionid=443788A5644E2BC100B4B2DB7758A0F8;jsessionid=D5910CF695459A7E16D5E2ED4D57B26D;jsessionid=ADB88245153F47A8DB7FFAB918534039;jsessionid=419D678EC78D9600BBD4A29EF0D1DC70